CLINICAL TRIALS PROFILE FOR XIFAXAN
✉ Email this page to a colleague
All Clinical Trials for XIFAXAN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00269399 ↗ | A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) | Completed | Bausch Health Americas, Inc. | Phase 3 | 2005-12-01 | The purpose of this study is to assess the treatment and safety of a 10-day course of rifaximin (Xifaxan) as compared to vancomycin for treatment of Clostridium difficile-associated diarrhea (CDAD). |
| NCT00269399 ↗ | A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) | Completed | Valeant Pharmaceuticals International, Inc. | Phase 3 | 2005-12-01 | The purpose of this study is to assess the treatment and safety of a 10-day course of rifaximin (Xifaxan) as compared to vancomycin for treatment of Clostridium difficile-associated diarrhea (CDAD). |
| NCT00577772 ↗ | Transit Time and Bacterial Overgrowth Using SmartPill Capsule | Terminated | The SmartPill Corporation | N/A | 2007-11-01 | The primary purpose of this exploratory study is to measure orocecal transit time using the SmartPill ambulant capsule technology and to compare this with the lactulose hydrogen breath test. Additionally, the ability of the SmartPill GI Monitoring System to discriminate between healthy human subjects and patients with small bowel bacterial overgrowth will be explored using analyses of both pH and pressure patterns within the stomach and small intestine. The study will be performed in both normal subjects and patients with and without small bowel bacterial overgrowth. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for XIFAXAN
Condition Name
Clinical Trial Locations for XIFAXAN
Trials by Country
Clinical Trial Progress for XIFAXAN
Clinical Trial Phase
Clinical Trial Sponsors for XIFAXAN
Sponsor Name
